LSL Pharma Group Inc (LSL-DB.CA) Fundamental Analysis & Valuation

TSX-V:LSL-DB

Current stock price

100 CAD
0 (0%)
Last:

This LSL-DB.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. LSL-DB.CA Profitability Analysis

1.1 Basic Checks

  • LSL-DB had negative earnings in the past year.
  • LSL-DB had a negative operating cash flow in the past year.
LSL-DB.CA Yearly Net Income VS EBIT VS OCF VS FCFLSL-DB.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 -2M -4M -6M -8M

1.2 Ratios

  • LSL-DB has a Return On Assets (-4.37%) which is comparable to the rest of the industry.
  • LSL-DB's Return On Equity of -8.14% is in line compared to the rest of the industry. LSL-DB outperforms 50.00% of its industry peers.
Industry RankSector Rank
ROA -4.37%
ROE -8.14%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LSL-DB.CA Yearly ROA, ROE, ROICLSL-DB.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 -100 -200 -300 -400

1.3 Margins

  • LSL-DB has a Gross Margin (25.13%) which is comparable to the rest of the industry.
  • LSL-DB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 25.13%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LSL-DB.CA Yearly Profit, Operating, Gross MarginsLSL-DB.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 0 -20 -40 -60 -80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. LSL-DB.CA Health Analysis

2.1 Basic Checks

  • LSL-DB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for LSL-DB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LSL-DB.CA Yearly Shares OutstandingLSL-DB.CA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 200K 400K 600K 800K
LSL-DB.CA Yearly Total Debt VS Total AssetsLSL-DB.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 5K 10K 15K 20K 25K

2.2 Solvency

  • LSL-DB has an Altman-Z score of 393.87. This indicates that LSL-DB is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 393.87, LSL-DB belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • A Debt/Equity ratio of 0.45 indicates that LSL-DB is not too dependend on debt financing.
  • LSL-DB's Debt to Equity ratio of 0.45 is fine compared to the rest of the industry. LSL-DB outperforms 75.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF N/A
Altman-Z 393.87
ROIC/WACCN/A
WACC7.66%
LSL-DB.CA Yearly LT Debt VS Equity VS FCFLSL-DB.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 -2M -4M -6M -8M

2.3 Liquidity

  • A Current Ratio of 1.17 indicates that LSL-DB should not have too much problems paying its short term obligations.
  • LSL-DB has a worse Current ratio (1.17) than 75.00% of its industry peers.
  • A Quick Ratio of 0.50 indicates that LSL-DB may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.50, LSL-DB is doing worse than 75.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.17
Quick Ratio 0.5
LSL-DB.CA Yearly Current Assets VS Current LiabilitesLSL-DB.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 50K 100K 150K 200K 250K

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. LSL-DB.CA Growth Analysis

3.1 Past

  • The earnings per share for LSL-DB have decreased strongly by -17.11% in the last year.
EPS 1Y (TTM)-17.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%59.61%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LSL-DB.CA Yearly Revenue VS EstimatesLSL-DB.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2M 4M 6M 8M 10M

More info and screens

Find the best growth stocksShow best growing peers

1

4. LSL-DB.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • LSL-DB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LSL-DB.CA Price Earnings VS Forward Price EarningsLSL-DB.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, LSL-DB is valued a bit cheaper than the industry average as 75.00% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 10620.58
LSL-DB.CA Per share dataLSL-DB.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 0.1 0.15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LSL-DB.CA Dividend Analysis

5.1 Amount

  • LSL-DB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

LSL-DB.CA Fundamentals: All Metrics, Ratios and Statistics

LSL Pharma Group Inc

TSX-V:LSL-DB (5/6/2025, 7:00:00 PM)

100

0 (0%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)N/A
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners23.12%
Ins Owner ChangeN/A
Market Cap11.55B
Revenue(TTM)15.82M
Net Income(TTM)-1.66M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 730.22
P/FCF N/A
P/OCF N/A
P/B 567.19
P/tB 1028.67
EV/EBITDA 10620.58
EPS(TTM)-0.02
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.14
BVpS0.18
TBVpS0.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -4.37%
ROE -8.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 25.13%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF N/A
Debt/EBITDA 8.35
Cap/Depr 206.6%
Cap/Sales 16.69%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.17
Quick Ratio 0.5
Altman-Z 393.87
F-ScoreN/A
WACC7.66%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.44%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%59.61%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-2755.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

LSL Pharma Group Inc / LSL-DB.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of LSL Pharma Group Inc (LSL-DB.CA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to LSL-DB.CA.


Can you provide the valuation status for LSL Pharma Group Inc?

ChartMill assigns a valuation rating of 1 / 10 to LSL Pharma Group Inc (LSL-DB.CA). This can be considered as Overvalued.


How profitable is LSL Pharma Group Inc (LSL-DB.CA) stock?

LSL Pharma Group Inc (LSL-DB.CA) has a profitability rating of 1 / 10.


What is the financial health of LSL Pharma Group Inc (LSL-DB.CA) stock?

The financial health rating of LSL Pharma Group Inc (LSL-DB.CA) is 3 / 10.